Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies. [electronic resource]
- Annals of hepatology
- 5-16 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
1665-2681
10.1016/j.aohep.2019.09.009 doi
Abatacept--therapeutic use Anti-Bacterial Agents--therapeutic use Azetidines--therapeutic use Benzothiazoles--therapeutic use Bezafibrate--therapeutic use Chalcones--therapeutic use Chenodeoxycholic Acid--analogs & derivatives Cholagogues and Choleretics--therapeutic use Cholangitis, Sclerosing--drug therapy Fecal Microbiota Transplantation Fibroblast Growth Factors--analogs & derivatives Gastrointestinal Microbiome Humans Immunologic Factors--therapeutic use Isoxazoles--therapeutic use Janus Kinase Inhibitors--therapeutic use Liver Cirrhosis, Biliary--drug therapy Peroxisome Proliferator-Activated Receptors--agonists Propionates--therapeutic use Purines--therapeutic use Pyrazoles--therapeutic use Pyrazolones--therapeutic use Pyridones--therapeutic use Receptors, Cytoplasmic and Nuclear--agonists Steroids--therapeutic use Sulfonamides--therapeutic use Tretinoin--therapeutic use Ursodeoxycholic Acid--therapeutic use Ustekinumab--therapeutic use